N
Google TrendPOSICIONES DE ATLÉTICO DE MADRID CONTRA MANCHESTER UNITED (5000+) — Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+luis díaz200+halle berry child custody hearing200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Intellia Therapeutics (NT" (15 stories)

Top Headline Story

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Lead StoryIntellia Therapeuticsgeneral
Nov 10, 2025

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNenNmcmhlU0lsRTRMNGQtb2VObzMySnJlNDBURzJtQmFseDN2NEpSY19ZVW16bHhBM0hOTkNfdV9KbUo5dXd0TDdHZjdfcXJxbEpDVGp0bExIVG44U0tsV1YzQnRkaDlDQS0zdHFEUGh6VjZEdEZoV3FrWnBTdmhzRE1saXNQdXBNSnhJRjlCOGpRdE9XTVI2Rnl5T2JhcFlVcDF4b2plQ0ZSNmlZOW5FWm5ITTFRbFNnOGxsQjZuMDFuT2c?oc=5" target="_blank">Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy</a>  <font color="#6f6f6f">Intellia Therapeutics</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+18m ago

posiciones de atlético de madrid contra manchester united

Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League

Filter stories
2000+18m ago

devils vs red wings

Devils at Red Wings projected lineups

Filter stories
5000+18m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+28m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories

Search Results for "Intellia Therapeutics (NT"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

14 stories displayed
Intellia Therapeutics Stock: Steady Progress, Historic Commercial Approval (NASDAQ:NTLA)
Seeking Alphamarkets

Intellia Therapeutics Stock: Steady Progress, Historic Commercial Approval (NASDAQ:NTLA)

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPa2JqcDFJbXFMM0ZYUE93NXJMU1MyOFFteVRVcmdQOElTTVR2OE54OFdqQWt4eFRXNFZQZC05NndYU0ZKbFdZMW9PVkhJQ1hEVmZiQXlfSG5jMVFVUDB2X3ZGUmRvVm5EV3F6Q2JVM0htaC1MRWNJdmVCdFJLUTBqakwteVB6b2JvVmE2Z1RxWHhOc28wZnBLZEpoSF9HdW1FTGlYMXE1RVJnNXZwMTBhR001cS1vUzg?oc=5" target="_blank">Intellia Therapeutics Stock: Steady Progress, Historic Commercial Approval (NASDAQ:NTLA)</a>  <font color="#6f6f6f">Seeking Alpha</font>

Read Full StoryMore like this
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
The Motley Foolmarkets

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQSTBlc2YxdlVpQ1B2Umo1VXFyaE9UaUlRZ0YwUXRJY1RZdWpibi0xTVhZTFQ5VkFHSkMxRkh2b3YwdnFWSTQxNU5oSURnZ3haTl9RTWFSRkJjSTNQWFpwdlBsd0phRWE5dGcwZm9FYkZ1TDcxTGlJX3lRcVJvTGw5UXZqb3JQMXFyNkc4dHdPUWdEYTkybkZIZA?oc=5" target="_blank">2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street</a>  <font color="#6f6f6f">The Motley Fool</font>

Read Full StoryMore like this
Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility (NTLA)
Seeking Alphageneral

Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility (NTLA)

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQWdzZjhRekNab1NEbGdpc3k4SVFlaVlndlVvQ3pNUGVGRlZ6emk4THB2dEdSMndBRjlJcmZRVFN4M1Jua3IxYmJpc2hvUTFnakVMOHlKU2YzU1l5SDdrX0I0UVFvYlNvMG9MOGZYaGlQME5hZ3dDb3pFdnJKWXBqZDl2SmdHczVpaHJ6ZHNWWVJwR1RtVHIyMW8xNDFhT2dpQ1daZHI2LXltZi1tV2hiMTlyb05PbUZz?oc=5" target="_blank">Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility (NTLA)</a>  <font color="#6f6f6f">Seeking Alpha</font>

Read Full StoryMore like this
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Intellia Therapeuticsworld

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOR1JPWS0yQVpEUUxhTXpXTm9vZlZIb1JBTHlTRG9GWnI0cndQdzV2a3J1eXlMVDhUdjY2bnM5RVFIS1NLSXlIa29JTnlseVJrbEIzYkIxdFpwV3lhQW5zYTU3cXBINkdEQzdYdGtYQ2d1VUZmT2lkLWRnYUtuc2ZOOFRuSUpxZFg2RzU1bVUzeFAyRmpLTENvRk54dXVyM2lTNnhPQVhEdUF3VjZjdjFQaVJmSzZJcDB5X3h0eFBISTRka2M?oc=5" target="_blank">Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis</a>  <font color="#6f6f6f">Intellia Therapeutics</font>

Read Full StoryMore like this
Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients
STATtech

Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPcGxKcjBnYjRUUldIclZuUndNdWRheW5JU0d3NmVGcjJhT3ctVFVYcWdHaG9EaWN6SHRwWnhtbVNObElDdkNJQWpIUVdBR2gwU2FBd3dWS3laUG8wV2RvdXNMM1IwVUJqbldjUHI2R29KZkRoNHVOUFJiRGJmRkdjV3NB?oc=5" target="_blank">Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia
Genetic Engineering and Biotechnology Newsmarkets

StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOQ2o1RGhNWXdZNGRISk51aEIyT0s2QWF1dXFkcjZNLXNKdWJ0Y2YzMGxGNnllQUQ1R1ljcjlScWZKMUdJdDEtaFJpNnVHdy1wQzdrekxiR1J2TklJcVVSa3lGUHhIRmR2V1YyZ0FGdE1PaGszdW10Rko2eVJFOHZwUmgta0JVOXgyLUxIQVVrcXQydU1uUXBvUXBzZzJPWTIyeXJ6QV9EYUwyV1g5NTVCRVl0dms1aEs3RTZEREo3S0RaMUNQ?oc=5" target="_blank">StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia</a>  <font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>

Read Full StoryMore like this
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
NEJMgeneral

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1HeFNqQjBJb1NSdTlvZkd4aHZKWmVSMDUzT1U2REtaQkxjLVItTDNISGtNaTA5NVpOcDRackRvbWJZbkwySnpnT05nRDF3X3BYTkl4T0J2ZThxSkdBY3lKYQ?oc=5" target="_blank">CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Intellia Therapeutics (NTLA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NTLA
MarketBeatgeneral

Intellia Therapeutics (NTLA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NTLA

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE1MMERhd2lFZFJzY3p6UHR0by1ERElRRUpLZEdxbE1rLUxfdk91MW1fMG1QZ2FiNExQalBsbWNWQ3BhRE45VmF6NlE4Q2NSekhGcW1qUnFPSk1iVWRNOEw1UjNxUFA4WWZ5?oc=5" target="_blank">Intellia Therapeutics (NTLA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NTLA</a>  <font color="#6f6f6f">MarketBeat</font>

Read Full StoryMore like this
Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression
TCTMD.comgeneral

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPTFc5NHZ1Q0VjbTcxakJ4SGFuanpETFdvOXNSd1BWc3JLMy1zMzVDRVF0Q1FWSzBkQkxoYkk0Qnp3ckF0N0FYME5RSXptbVlWZlpadkxqRmluZXVpMTBsV0lsWFpoaGVCOXRXcmFZTENYWjlfU3NjaFJ1ZWFCYTRoZm04djM?oc=5" target="_blank">Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression</a>  <font color="#6f6f6f">TCTMD.com</font>

Read Full StoryMore like this
CRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin Amyloidosis
Neurology Todaygeneral

CRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin Amyloidosis

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFB5d21VR0stdFhLY19zMDdXTFZiR0FPOE80bFk2eC1VeVhGd3EwQmhTNGVWUU1UZnBTQUNlSGluZHBCQWRCcWE5c2FFU1hoRWp3MXA2WUhKSm9wV1pOelBLbmxiRFh1MU5nUVM3WUo2RUItOTlRVHNZ?oc=5" target="_blank">CRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin Amyloidosis</a>  <font color="#6f6f6f">Neurology Today</font>

Read Full StoryMore like this
Comparison of Fixed vs Age-Adjusted NT-proBNP Cutoffs to Define Pre–Heart Failure:
JACC Journalstech

Comparison of Fixed vs Age-Adjusted NT-proBNP Cutoffs to Define Pre–Heart Failure:

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9yTFpDaGJKQU5oNkl5UmduclpVOUxva1c5VlltVXR3SmtCdDBPVEliS0FQdkJfYmlWMUlWdER4d0ZrN01WT1BnV1RwQ1pFQUltc0hReUxmUEs5eHdReTVVYg?oc=5" target="_blank">Comparison of Fixed vs Age-Adjusted NT-proBNP Cutoffs to Define Pre–Heart Failure:</a>  <font color="#6f6f6f">JACC Journals</font>

Read Full StoryMore like this
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
The Motley Foolmarkets

This Beaten-Down Stock Could Soar by 354%, According to Wall Street

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxONXlVZ19kSGg1eVd1VVlGOFI1bVNlSE5CaERMTmlpcHBYMXdxSEhMWUdBS2p0ZUMtR0FNMDVGUHlOLUw1TDJEN3dNVmIyWXJRT1lyQkRjMUNXQjFCTTZCX3lONFFiMVlhVkt6Z2FpVG5oZkY1N0hVVGstOEx1czhpSlBmSXFsZnlWZjZTbU5lN1NTNDNLcTJwSA?oc=5" target="_blank">This Beaten-Down Stock Could Soar by 354%, According to Wall Street</a>  <font color="#6f6f6f">The Motley Fool</font>

Read Full StoryMore like this
Intellia Therapeutics - NTLA - Stock Price & News
The Motley Foolmarkets

Intellia Therapeutics - NTLA - Stock Price & News

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE91cXJJSEphVFBWamE3TWF5T3RPOEVlalB1cEQ1UmVTc0daTU9EY2hTX2ZTcEl2QV8yTmZvTVFIei1xZkthdXVrSDliZGJuTzdv?oc=5" target="_blank">Intellia Therapeutics - NTLA - Stock Price & News</a>  <font color="#6f6f6f">The Motley Fool</font>

Read Full StoryMore like this
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The Motley Foolgeneral

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOVEhtRm5YaXhlVkZuaHNvVndZSm0zUmtrS3JKZ21UV2RSVE11eEV5Q3U0clV1cHVVVkE4WldhVjJReUViQVdyYWppMXhRSEhQMXpIQWJwQ21valFGUFBWckxob2c3T09ZLWpldGF4eHQ3LWJRS3NjZUVMc3F6Xzk4MXhtZVd1TXV6R1hRbDdBNEhDUXdhVHFn?oc=5" target="_blank">You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.</a>  <font color="#6f6f6f">The Motley Fool</font>

Read Full StoryMore like this
"Intellia Therapeutics (NT" — Live Google News Trends & Headlines